TTC28

Across TCGA pan-cancer cohorts, TTC28 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TTC28 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TTC28 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC28 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where TTC28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.477	0.916	<.001	38	view →
CCRCC	DFS	Median	All	0.623	0.840	.009	13	view →
GBM	OS	Tertile	All	0.692	0.417	.001	11	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	6	view →
LSCC	DFS	Quartile	All	0.355	1.000	.006	6	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.479	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TTC28–PDAC (DFS)

Open the PDAC breakdown →